Company Filing History:

5 out of 1,304

Stauffer Chemical Company

patents

Imperial Chemical Industries Limited

Years Active: 1983-2011

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7951972 - Human adam-10 inhibitors (2011-05-31),

2. 7498358 - Human ADAM-10 inhibitors (2009-03-03),

3. 5714438 - Herbicidal 5-substituted pyrimidine compounds and derivatives thereof (1998-02-03),

4. 5550165 - Pharmaceutical compositions for the treatment of hereditary tyosinemia (1996-08-27),

5. 5278133 - Pyridone herbicides (1994-01-11),

6. 5260261 - Fused pyridine herbicides (1993-11-09),

7. 5022915 - Substituted 2,4-diarylpyrimidines and their use as herbicides (1991-06-11),

8. 4958028 - Process for the preparation of 5-substituted-3-phenyl (1990-09-18),

9. 4911748 - Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones (1990-03-27),

10. 4871391 - Herbicidal 5-substituted-2-4-imidazolidinediones (1989-10-03),

11. 4859228 - Novel 5-aminomethylene-2,4-imidazolidinediones and (1989-08-22),

12. 4714491 - Diphenyl ether herbicides (1987-12-22),

13. 4481026 - Aluminum N-phosphonomethylglycine and its use as a herbicide (1984-11-06),

14. 4472189 - Stannic N-phosphonomethyglycine and its use as a herbicide (1984-09-18),

15. 4464194 - Mixed alkylsulfonium salts of N-phosphonomethylglycine (1984-08-07),

Title: Michael P Prisbylla: A Pioneer in ADAM-10 Inhibition Research

Introduction

Michael P Prisbylla, an accomplished inventor based in Richmond, CA, has made significant contributions to the field of pharmaceuticals with a focus on innovations related to ADAM-10 inhibitors. With an impressive portfolio of 16 patents, his work is paving the way for new treatments in various medical conditions.

Latest Patents

Among his latest innovations, Michael has developed a series of human ADAM-10 inhibitors. These compounds are designed to inhibit the ADAM-10 protein, which plays a critical role in various biological processes. His inventions encompass pharmaceutical compositions that combine these inhibitors with pharmaceutically acceptable carriers. Such compositions are particularly useful for treating cancer, arthritis, and diseases associated with angiogenesis. Additionally, the patents detail methods for formulating bis-aryl ether sulfonyl chlorides and ADAM-10 modulators, emphasizing the broad applicability of his research.

Career Highlights

Michael's career includes significant tenures at notable companies such as Stauffer Chemical Company and International Chemical Industries Americas, Inc. His experiences in these organizations have influenced his innovative approach to pharmaceutical development and have provided a solid foundation for his research endeavors.

Collaborations

Throughout his career, Michael has worked alongside esteemed colleagues like S David Brown and Lynne Canne-Bannen. These collaborations have further enriched his research and have likely contributed to the successful realization of his patents and inventions.

Conclusion

Michael P Prisbylla stands as a prominent figure in the realm of pharmaceutical innovation, particularly in the development of ADAM-10 inhibitors. His work not only showcases his inventive spirit but also holds promise for advancing treatments for significant medical conditions. With his continued research and development efforts, he is set to make even greater contributions to the field in the years to come.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com